These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36908162)

  • 41. Limitations to antiarrhythmic drug use in patients with atrial fibrillation.
    Humphries KH; Kerr CR; Steinbuch M; Dorian P;
    CMAJ; 2004 Sep; 171(7):741-5. PubMed ID: 15451836
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Flecainide-Induced Atrial Flutter With 1:1 Conduction Complicated by Ventricular Fibrillation After Electrical Cardioversion.
    Colangelo T; Johnson D; Ho R
    Tex Heart Inst J; 2021 Jun; 48(2):. PubMed ID: 34086956
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome.
    O'Nunain S; Garratt CJ; Linker NJ; Gill J; Ward DE; Camm AJ
    Pacing Clin Electrophysiol; 1991 Nov; 14(11 Pt 2):2028-34. PubMed ID: 1721219
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Arrhythmias in the intensive care patient.
    Trappe HJ; Brandts B; Weismueller P
    Curr Opin Crit Care; 2003 Oct; 9(5):345-55. PubMed ID: 14508146
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
    Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
    Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety issues in the treatment of paediatric supraventricular tachycardias.
    Pfammatter JP; Bauersfeld U
    Drug Saf; 1998 May; 18(5):345-56. PubMed ID: 9589846
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety of oral propafenone in the treatment of arrhythmias in infants and children (European retrospective multicenter study). Working Group on Pediatric Arrhythmias and Electrophysiology of the Association of European Pediatric Cardiologists.
    Janousek J; Paul T
    Am J Cardiol; 1998 May; 81(9):1121-4. PubMed ID: 9605053
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation.
    Freemantle N; Lafuente-Lafuente C; Mitchell S; Eckert L; Reynolds M
    Europace; 2011 Mar; 13(3):329-45. PubMed ID: 21227948
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of long-term oral flecainide acetate in patients with responsive supraventricular tachycardia.
    Hellestrand KJ
    Am J Cardiol; 1996 Jan; 77(3):83A-88A. PubMed ID: 8607396
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Flecainide and encainide.
    Furlanello F; Vergara G; Bettini R; Mosna G; Gramegna L; Disertori M
    Eur Heart J; 1987 Mar; 8 Suppl A():33-40. PubMed ID: 3107989
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proarrhythmic Effects Of Antiarrhythmic Drugs: Case Study Of Flecainide Induced Ventricular Arrhythmias During Treatment Of Atrial Fibrillation.
    Barman M
    J Atr Fibrillation; 2015 Dec; 8(4):1091. PubMed ID: 27957216
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia.
    Prystowsky EN
    Clin Cardiol; 1994 Sep; 17(9 Suppl 2):II7-10. PubMed ID: 7882612
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia.
    Kuck KH; Kunze KP; Schlüter M; Duckeck W
    Am J Cardiol; 1988 Dec; 62(19):37L-44L. PubMed ID: 3144166
    [TBL] [Abstract][Full Text] [Related]  

  • 54. European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias.
    Coumel P; Leclercq JF; Assayag P
    Am J Cardiol; 1984 Nov; 54(9):60D-66D. PubMed ID: 6208770
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
    Manz M; Lüderitz B
    Eur Heart J; 1993 Sep; 14 Suppl E():91-8. PubMed ID: 8223763
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Electropharmacological test with class-I C drugs in paroxysmal supraventricular re-entrant tachycardia: is a negative result with a drug predictive of the ineffectiveness of other drugs of the same class?].
    Inama G; Furlanello F; Braito G; Guarnerio M; Vergara G
    G Ital Cardiol; 1991 Feb; 21(2):131-8. PubMed ID: 1907937
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation.
    Herre JM; Titus C; Oeff M; Eldar M; Franz MR; Griffin JC; Scheinman MM
    Ann Intern Med; 1990 Nov; 113(9):671-6. PubMed ID: 2121082
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation.
    Falk RH
    Ann Intern Med; 1989 Jul; 111(2):107-11. PubMed ID: 2500880
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Flecainide therapy in patients treated for supraventricular tachycardia with near normal left ventricular function.
    Hughes MM; Trohman RG; Simmons TW; Castle LW; Wilkoff BL; Morant VA; Maloney JD
    Am Heart J; 1992 Feb; 123(2):408-12. PubMed ID: 1736577
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.